ArticleMolecular therapy. Methods & clinical development2025

AAV-shDUX4 provides short-term benefits but limited long-term efficacy in a DUX4 mouse model of FSHD.

S Sohn et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.